U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD 20993, USA.
Viruses. 2023 Jun 28;15(7):1466. doi: 10.3390/v15071466.
Transmissible spongiform encephalopathies (TSEs) or prion diseases are characterized by the accumulation in affected tissues of the abnormal prion protein PrP. We previously demonstrated PrP in the blood of macaques experimentally infected with variant Creutzfeldt-Jakob disease (vCJD), a human TSE, months to years prior to clinical onset. That work supported the prospect of using PrP as a blood biomarker to detect vCJD and possibly other human TSEs before the onset of overt illness. However, our results also raised questions about the origin of PrP detected in blood early after inoculation and the effects of dose and route on the timing of the appearance of PrP. To investigate these questions, we inoculated vCJD-susceptible transgenic mice and non-infectable prion protein-knockout mice under inoculation conditions resembling those used in macaques, with additional controls. We assayed PrP in mouse blood using the protein misfolding cyclic amplification (PMCA) method. PrP from the inoculum cleared from the blood of all mice before 2 months post-inoculation (mpi). Mouse PrP generated de novo appeared in blood after 2 mpi. These results were consistent regardless of dose or inoculation route. We also demonstrated that a commercial ELISA-like PrP test detected and quantified PMCA products and provided a useful alternative to Western blots.
传染性海绵状脑病(TSEs)或朊病毒病的特征是受影响组织中异常朊病毒蛋白 PrP 的积累。我们之前证明了在实验感染变异型克雅氏病(vCJD)的猕猴的血液中有 PrP,vCJD 是一种人类 TSE,在临床发病前数月至数年。这项工作支持了使用 PrP 作为血液生物标志物来检测 vCJD 并可能在明显疾病发作前检测其他人类 TSE 的前景。然而,我们的结果也提出了一些关于接种后早期血液中检测到的 PrP 的来源以及剂量和途径对 PrP 出现时间的影响的问题。为了研究这些问题,我们在类似于猕猴中使用的接种条件下接种了易感 vCJD 的转基因小鼠和不可感染的朊病毒蛋白敲除小鼠,并进行了额外的对照。我们使用蛋白错误折叠循环扩增(PMCA)法检测了小鼠血液中的 PrP。接种后所有小鼠的血液中的接种物清除 PrP 都在 2 个月内(mpi)。在 2 mpi 后,新生成的小鼠 PrP 出现在血液中。无论剂量或接种途径如何,这些结果都是一致的。我们还证明了一种商业 ELISA 样 PrP 检测可以检测和定量 PMCA 产物,并且是 Western blot 的有用替代方法。